BridgeBio Pharma has entered into an agreement with Alexion Pharmaceuticals to acquire cyclic pyranopterin monophosphate (cPMP; ALXN1101), a synthetic enzyme co-factor therapy for patients with the ultra-rare disease caused by molybdenum cofactor deficiency (MoCD) Type A.
Sanofi Pasteur, the vaccines business of French pharma firm Sanofi, has agreed to acquire exclusive license of Translate Bio’s mRNA technology to develop messenger RNA (mRNA) vaccines in a deal that could be worth up to $805m.
Oncologie is launching operations in both Boston and Shanghai with $16.5m seed financing led by Pivotal bioVenture Partners China.
Sirnaomics, a biopharmaceutical company in development of RNAi therapeutics, has closed Series C1 financing of $25m.
Pfizer said that it will invest $600m in biotechnology and other emerging growth firms through its venture capital arm Pfizer Ventures for the development of life-changing therapies to patients in need.
Nimbus Therapeutics has raised $65m in new capital to accelerate its pipeline progress and fuel its expansion into new high-value targets aimed at overlapping biological mechanisms in immunology, oncology and metabolic disease.
Privately held clinical stage biopharmaceutical firm ENYO Pharma has completed a €40m series B round of financing from US and European investors.
Cara Therapeutics has granted licensing worldwide rights with the exception of the US, Japan and South Korea to commercialize its Korsuva (CR845/difelikefalin) injection to Vifor Fresenius Medical Care Renal Pharma (VFMCRP).
Alivio Therapeutics, an affiliate of PureTech Health, announced that the US Patent and Trademark Office (USPTO) issued U.S. Patent Nos. 9,962,339 and 9,974,859, related to its inflammation-targeting technology platform.
Roche's Hemlibra (emicizumab) has significantly reduced bleeding in hemophilia patients, which was demonstrated in two phase 3 Haven studies.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.